A genome-scale screen for synthetic drivers of T cell proliferation.

A genome-scale screen for synthetic drivers of T cell proliferation.
复制标题

DOI:
10.1038/s41586-022-04494-7
复制
发表时间:
2022-03
期刊:
影响因子:
64.8
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

用于过继性细胞疗法的患者T细胞工程已经彻底改变了多种癌症类型的治疗。然而,需要进一步改进,以提高反应率和治愈率。基于CRISPR的功能丧失筛选仅限于T细胞功能的负调节因子,并由于永久性基因组修饰而引起安全性问题。在这里,我们通过~ 12,000个条形码化的人类开放阅读框(ORF)的过表达来鉴定阳性T细胞调节因子。排名靠前的基因增加了原代人CD 4+和CD 8 + T细胞的增殖、活化和关键细胞因子如白细胞介素-2和干扰素-γ的分泌。此外,我们开发了一种单细胞基因组学方法(OverCITE-seq),用于高通量定量ORF工程化T细胞中的转录组和表面抗原。排名第一的ORF,光毒素β受体(LTBR),通常在骨髓细胞中表达,但在淋巴细胞中不存在。当在T细胞中过表达时,LTBR通过典型NF-κB通路的组成性激活诱导了深刻的转录和表观基因组重构,增加了T细胞效应器功能,以及在慢性刺激环境中对耗竭的抵抗。LTBR和其他排名靠前的基因改善了抗原特异性嵌合抗原受体(CAR)T细胞和γδ T细胞反应,突出了它们在未来癌症不可知疗法中的潜力。我们的研究结果提供了几种通过诱导新的合成细胞程序来改善下一代T细胞疗法的策略。
The engineering of patient T-cells for adoptive cell therapies has revolutionised the treatment of several cancer types. However, further improvements are needed to increase response and cure rates. CRISPR-based loss-of-function screens have been limited to negative regulators of T-cell functions and raise safety concerns due to permanent genome modification. Here we identify positive T-cell regulators via overexpression of ~12,000 barcoded human open reading frames (ORFs). The top-ranked genes increased primary human CD4+ and CD8+ T-cell proliferation, activation, and secretion of key cytokines like interleukin-2 and interferon-gamma. In addition, we developed a single-cell genomics method (OverCITE-seq) for high-throughput quantification of the transcriptome and surface antigens in ORF-engineered T-cells. The top-ranked ORF, lymphotoxin beta receptor (LTBR), is typically expressed in myeloid cells but absent in lymphocytes. When overexpressed in T-cells, LTBR induced profound transcriptional and epigenomic remodelling, increasing T-cell effector functions, as well as resistance to exhaustion in chronic stimulation settings, via constitutive activation of the canonical NF-κB pathway. LTBR and other top-ranked genes improved antigen-specific chimeric antigen receptor (CAR) T-cell and γδ T-cell responses, highlighting their potential for future cancer-agnostic therapies. Our results provide several strategies for improving next generation T-cell therapies via induction of new synthetic cell programmes.
DOI: 10.1016/s1074-7613(02)00423-5
发表时间: 2002-10-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Dejardin, E;Droin, NM;Green, DR
通讯作者: Green, DR
DOI: 10.1038/nbt.4314
发表时间: 2019-01-01
影响因子: 46.9
作者:
Becht, Etienne;McInnes, Leland;Newell, Evan W.
通讯作者: Newell, Evan W.
DOI: 10.1038/nmeth.1923
发表时间: 2012-03-04
期刊: NATURE METHODS
影响因子: 48
作者:
Langmead, Ben;Salzberg, Steven L.
通讯作者: Salzberg, Steven L.
DOI: 10.1016/j.celrep.2020.02.010
发表时间: 2020-03-03
期刊: Cell reports
影响因子: 8.8
作者:
Legut M;Daniloski Z;Xue X;McKenzie D;Guo X;Wessels HH;Sanjana NE
通讯作者: Sanjana NE
DOI: 10.1016/j.cell.2019.07.044
发表时间: 2019-08-22
期刊: CELL
影响因子: 64.5
作者:
Dong, Matthew B.;Wang, Guangchuan;Chen, Sidi
通讯作者: Chen, Sidi